- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Palatin finalizes partnership with Mallinckrodt
The marketing alliance between biopharmaceutical start-up Palatin and healthcare giant Mallinckrodt for Palatin’s radiolabeled infection imaging agent, LeuTech (SCAN 5/26/99), has become official. Under the terms of the agreement,
The marketing alliance between biopharmaceutical start-up Palatin and healthcare giant Mallinckrodt for Palatins radiolabeled infection imaging agent, LeuTech (SCAN 5/26/99), has become official. Under the terms of the agreement, Mallinckrodt paid Palatin a licensing fee of $500,000 and acquired 700,000 restricted unregistered shares of Palatin preferred stock for an additional $13 million. An extra $10 million in milestone payments will be paid to Palatin upon Food and Drug Administration approval of the first indication for LeuTech, and the attainment of certain sales goals following the commercial introduction of this product. St. Louis-based Mallinckrodt will also reimburse Palatin for 50% of all ongoing LeuTech development costs, while Palatin, which is based in Princeton, NJ, will manufacture LeuTech and receive a transfer price on each product unit and a royalty on net LeuTech sales.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
